Company intelligence / Profile preview
Guangzhou Enbao Biomedical Technology
Guangzhou, Guangdong, Chinagznbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Guangzhou Enbao Biomedical Technology specializes in the R&D of prophylactic and recombinant vector vaccines for infectious diseases, with their lead product—a recombinant Covid-2019 vaccine (Adenovirus type 5 vector)—in Phase 2 clinical trials for COVID-19. Their pipeline also includes preclinical prophylactic vaccines targeting SARS-CoV-2 S protein for coronavirus infections[2][3].
- Therapeutic areas
- Infectious Diseases
- Modalities
- Prophylactic vaccineRecombinant vector vaccine
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Hualan Biological Bacterin
Beyond the preview
Go deeper on Guangzhou Enbao Biomedical Technology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Guangzhou Enbao Biomedical Technology.